Update on Bimervax® Immunogenicity Amplitude. Insights on Humoral Response Against XBB.1.5 from an Extension Study (NTC05142553)

Kurhade C, Zou J, Xia H, Liu M, Chang H, Ren P . Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. 2022; 29(2):344-347. DOI: 10.1038/s41591-022-02162-x. View

Devasundaram S, Terpos E, Rosati M, Ntanasis-Stathopoulos I, Bear J, Burns R . XBB.1.5 neutralizing antibodies upon bivalent COVID-19 vaccination are similar to XBB but lower than BQ.1.1. Am J Hematol. 2023; 98(5):E123-E126. PMC: 10116518. DOI: 10.1002/ajh.26887. View

Corominas J, Garriga C, Prenafeta A, Moros A, Canete M, Barreiro A . Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. Lancet Reg Health Eur. 2023; 28:100613. PMC: 10102678. DOI: 10.1016/j.lanepe.2023.100613. View

Sutandhio S, Furukawa K, Kurahashi Y, Marini M, Effendi G, Hasegawa N . Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population. J Infect Public Health. 2023; 16(7):1064-1072. PMC: 10163793. DOI: 10.1016/j.jiph.2023.05.004. View